Open AccessOrgan dysfunction in critically ill cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Author(s) -
Silvio A. ÑamendysSilva,
Paulina CorreaGarcía,
Francisco J. GarcíaGuillén,
Horacio Noé López-Basave,
Gonzalo MontalvoEsquivel,
Julia TexcocanoBecerra,
Ángel HerreraGómez,
Abelardo MenesesGarcía
Publication year - 2015
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2015.2921
Subject(s) - cytoreductive surgery , medicine , cancer , hyperthermic intraperitoneal chemotherapy , critically ill , intraperitoneal chemotherapy , chemotherapy , intensive care medicine , molecular medicine , cancer surgery , organ dysfunction , oncology , ovarian cancer , cell cycle , sepsis
The aim of the present study was to observe the incidence of organ dysfunction and the intensive care unit (ICU) outcomes of critically ill cancer patients during the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy post-operative period. The present study included 25 critically ill cancer patients admitted to the ICU of the National Cancer Institute (Mexico City, Mexico) between January 2007 and February 2013. The incidence of organ dysfunction was 68% and patients exhibiting ≤1 organ system dysfunction during ICU admittance remained in hospital for a significantly shorter period compared with patients who exhibited ≥2 organ system dysfunctions (12.4±10.7 vs. 24.1±12.8 days; P=0.025). Therefore, the present study demonstrated that a high incidence of organ dysfunction was associated with a longer ICU hospital stay.